BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32829070)

  • 21. Concordance of folate receptor-α expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients.
    Boogerd LS; Boonstra MC; Beck AJ; Charehbili A; Hoogstins CE; Prevoo HA; Singhal S; Low PS; van de Velde CJ; Vahrmeijer AL
    Oncotarget; 2016 Apr; 7(14):17442-54. PubMed ID: 26943581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
    Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
    BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Expression of folate receptor alpha in ovarian epithelial tumors].
    Shen DH; Xie JL; Zhang YL; Wang Y
    Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):747-51. PubMed ID: 21215165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolactin receptor expression as a novel prognostic biomarker for triple negative breast cancer patients.
    Motamedi B; Rafiee-Pour HA; Khosravi MR; Kefayat A; Baradaran A; Amjadi E; Goli P
    Ann Diagn Pathol; 2020 Jun; 46():151507. PubMed ID: 32199279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
    Choi JE; Kang SH; Lee SJ; Bae YK
    Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients.
    Urru SAM; Gallus S; Bosetti C; Moi T; Medda R; Sollai E; Murgia A; Sanges F; Pira G; Manca A; Palmas D; Floris M; Asunis AM; Atzori F; Carru C; D'Incalci M; Ghiani M; Marras V; Onnis D; Santona MC; Sarobba G; Valle E; Canu L; Cossu S; Bulfone A; Rocca PC; De Miglio MR; Orrù S
    BMC Cancer; 2018 Jan; 18(1):56. PubMed ID: 29310602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin growth factor receptor-1 expression and loss of PTEN protein predict early recurrence in triple-negative breast cancer.
    Iqbal J; Thike AA; Cheok PY; Tse GM; Tan PH
    Histopathology; 2012 Oct; 61(4):652-9. PubMed ID: 22759273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High expression of NR1D1 is associated with good prognosis in triple-negative breast cancer patients treated with chemotherapy.
    Na H; Han J; Ka NL; Lee MH; Choi YL; Shin YK; Lee MO
    Breast Cancer Res; 2019 Nov; 21(1):127. PubMed ID: 31779659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
    Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
    Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients.
    Ricciardi GR; Adamo B; Ieni A; Licata L; Cardia R; Ferraro G; Franchina T; Tuccari G; Adamo V
    PLoS One; 2015; 10(6):e0128368. PubMed ID: 26039245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer.
    Li X; Wetherilt CS; Krishnamurti U; Yang J; Ma Y; Styblo TM; Meisel JL; Peng L; Siddiqui MT; Cohen C; Aneja R
    Am J Clin Pathol; 2016 Oct; 146(4):496-502. PubMed ID: 27686176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of transforming growth factor-β1 in triple negative breast cancer patients.
    Zhang M; Wu J; Mao K; Deng H; Yang Y; Zhou E; Liu J
    Int J Surg; 2017 Sep; 45():72-76. PubMed ID: 28754615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Folate-appended cyclodextrin carrier targets ovarian cancer cells expressing the proton-coupled folate transporter.
    Saito S; Koya Y; Kajiyama H; Yamashita M; Kikkawa F; Nawa A
    Cancer Sci; 2020 May; 111(5):1794-1804. PubMed ID: 32154964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer.
    Ma F; Ding X; Fan Y; Ying J; Zheng S; Lu N; Xu B
    PLoS One; 2014; 9(11):e112765. PubMed ID: 25393310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
    Abd-Elazeem MA; Abd-Elazeem MA
    Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.
    Li Q; Jin W; Cai Y; Yang F; Chen E; Ye D; Wang Q; Guan X
    Biochem Biophys Res Commun; 2017 Apr; 485(3):693-697. PubMed ID: 28237701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Folate receptor-α (FOLR1) expression and function in triple negative tumors.
    Necela BM; Crozier JA; Andorfer CA; Lewis-Tuffin L; Kachergus JM; Geiger XJ; Kalari KR; Serie DJ; Sun Z; Moreno-Aspitia A; O'Shannessy DJ; Maltzman JD; McCullough AE; Pockaj BA; Cunliffe HE; Ballman KV; Thompson EA; Perez EA
    PLoS One; 2015; 10(3):e0122209. PubMed ID: 25816016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IgA Fc-folate conjugate activates and recruits neutrophils to directly target triple-negative breast cancer cells.
    Frontera ED; Khansa RM; Schalk DL; Leakan LE; Guerin-Edbauer TJ; Ratnam M; Gorski DH; Speyer CL
    Breast Cancer Res Treat; 2018 Dec; 172(3):551-560. PubMed ID: 30155754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of folate receptor alpha immunohistochemistry in cytology specimens of metastatic breast carcinoma, metastatic serous carcinoma of Müllerian origin, and primary lung adenocarcinoma.
    Sheikh UN; Cohen C; Siddiqui MT
    Diagn Cytopathol; 2016 May; 44(5):369-76. PubMed ID: 26875861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.
    Wen Y; Graybill WS; Previs RA; Hu W; Ivan C; Mangala LS; Zand B; Nick AM; Jennings NB; Dalton HJ; Sehgal V; Ram P; Lee JS; Vivas-Mejia PE; Coleman RL; Sood AK
    Clin Cancer Res; 2015 Jan; 21(2):448-59. PubMed ID: 25416196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.